Key Takeaways HSIC is set to report Q4 2025 results on Feb. 24, with revenues projected to rise 4.5% year over year.Henry Schein's Global Specialty Products revenues are expected to grow 5.9% on implant strength.HSIC's Global Technology sales are projected to jump 9.7% on SaaS and cloud momentum.Henry Schein, Inc. (HSIC) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which su ...

Core Insights - The fourth quarter of 2025 saw a strong divergence in market performance, with AI beneficiaries and cyclical sectors leading, while quality growth strategies faced challenges [1] - The SGA Emerging Markets Growth Strategy portfolio returned 0.8% (Gross) and 0.6% (Net) in Q4 2025, underperforming against the MSCI EM Net TR Index return of 4.7% and the MSCI EM Growth Net TR Index return of 3.3% [1] - For the full year 2025, the portfolio achieved returns of 23.8% (Gross) and 22.8% (Net), lagging behind the indexes which returned 33.6% and 34.3% respectively [1] - The portfolio anticipates annual revenue growth of 13% and earnings growth of 16% over the next three years [1] Company Insights - Alcon Inc. (NYSE:ALC) is highlighted as a key stock in the SGA Emerging Markets Growth Strategy, focusing on eye care products [2] - Alcon Inc. experienced a one-month return of 0.25% and a 12.05% decline in share value over the past 52 weeks, with a closing stock price of $79.20 and a market capitalization of $39.052 billion as of February 13, 2026 [2] - The SGA Emerging Markets Growth Strategy engaged with Alcon's leadership team in December 2025 to discuss ESG matters, specifically compensation and sustainability [3]

Core Insights - Positron Corporation has announced the sale of four PET-CT 64-slice scanners to three nuclear cardiology practices, highlighting the growing adoption of its advanced imaging technology and services [1][2] Group 1: Company Developments - The new customer engagements reflect the increasing preference for Positron's next-generation PET-CT technology, which offers integrated clinical, technical, and training support [2] - Positron's PET-CT scanners are designed to optimize clinical outcomes and operational efficiency, featuring a 72cm wide-bore gantry for patient comfort and high-sensitivity detector technology to reduce radiation exposure [3][4] - The company has over three decades of experience in supporting clinical scans, positioning itself as a trusted partner for nuclear cardiology practices transitioning to PET-CT imaging [5] Group 2: Industry Context - The shift towards cardiac PET imaging is driven by the need for superior clinical performance and sustainable economics, as providers move away from legacy imaging modalities [3] - Positron's advanced data acquisition capabilities enhance diagnostic confidence and expand the range of studies that can be performed, including myocardial perfusion and tumor detection [4] - The company aims to expand the cardiac and oncology PET modality by delivering advanced technology and value to imaging specialists, supported by its partnership with Shenyang Intelligent Neuclear Technology Co. [9]

Market Overview - US equity futures resumed their selloff after a brief bounce, with S&P 500 futures down 0.5% and Nasdaq 100 contracts falling 1.0%, driven by concerns over AI disruption [1] - All major tech stocks in the "Magnificent 7" are lower, with notable declines in Nvidia (-0.9%) and Alphabet (-1.5%) [3] - Energy, financials, industrials, and defensive sectors showed pockets of outperformance amid the broader market decline [1] Corporate News - Activist investor Elliott has built a significant stake in Norwegian Cruise Line, leading to a rise of over 7% in its shares [4] - Apple is set to hold a product launch on March 4, which may impact its stock performance [3] - ImmunityBio shares rose 6% after receiving encouragement from the Saudi Food and Drug Authority to submit a regulatory package for its bladder cancer therapy [4] - Masimo shares surged 34% following reports of a nearly $10 billion acquisition deal by Danaher [4] AI and Technology Sector - Investors are cautious about the profitability of AI spending, with concerns about competition and potential disruptions to various industries [6][7] - A record number of investors believe companies are overspending on AI, with 25% citing an "AI bubble" as a top market risk [10] - Despite selloff concerns, two-year forward earnings estimates for software stocks have risen, indicating resilience in the sector [11] Economic Indicators - Upcoming economic data includes the ADP employment change, Empire State manufacturing survey, and NAHB housing market index for February, which could influence market sentiment [1][22] - The UK unemployment rate rose to 5.2%, leading to increased expectations for a Bank of England rate cut [16] Commodities and Geopolitical Factors - Oil prices rose due to geopolitical tensions, particularly military drills by Iran in the Strait of Hormuz, impacting Brent crude prices [13][48] - Gold prices have declined, with spot gold dropping toward $4,900 an ounce amid a risk-off sentiment [1][48]

Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industryPRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief ...

Perimeter Announces Grant and Cancellation of Stock Options [Accessibility Statement] Skip NavigationTORONTO and DALLAS, Feb. 17, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announces its intention to enter into cancellation agreements with certain employees and consultants of the Company, pursuant to which it will cancel and grant stock options to such employees and consultants.The Company ...

Core Insights - Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton, expanding access to approximately 16 million beneficiaries in the U.S. [1][2] Group 1: Company Developments - Lifeward Ltd. announced that Aetna issued prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, recognizing it as medically necessary for individuals with spinal cord injuries [1][2] - The ReWalk Personal Exoskeleton is an FDA-approved technology that enables individuals with spinal cord injuries to achieve functional ambulation, with multiple peer-reviewed studies supporting its benefits [2][3] Group 2: Market Impact - The recent approvals for prior authorization from three major Medicare Advantage insurers signify a significant advancement in access to exoskeletal rehabilitation technology for patients and providers [3][4] - A nurse with a spinal cord injury expressed that access to the ReWalk device represents a life-changing opportunity, emphasizing the importance of innovative mobility devices for dignity and independence [4] Group 3: Company Mission and Products - Lifeward is committed to driving innovation in medical technology to improve the lives of individuals with physical limitations or disabilities, with a product portfolio that includes the ReWalk Exoskeleton and other rehabilitation solutions [6][7]

Core Insights - Sanara MedTech Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2 – 4, 2026, with a presentation scheduled for March 3 at 9:10 a.m. Eastern Time [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [3] - The company markets surgical products primarily in the North American surgical tissue repair market, including CellerateRX Surgical Activated Collagen Powder, BIASURGE Advanced Surgical Solution, and FORTIFY TRG Tissue Repair Graft [3] - Sanara aims to be an innovative provider of effective surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Core Viewpoint - BrainsWay Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to simplify comparisons and enhance liquidity for U.S. investors [1][4]. Group 1: ADS Ratio Change - The current 2-to-1 ordinary share-to-ADS ratio will be adjusted to a 1-to-1 structure, effective March 3, 2026 [2]. - Each existing ADS holder will receive one additional ADS for each ADS held, effectively acting as a 2-for-1 forward split [2][3]. - The trading price of the ADSs is expected to be halved following the ratio change [3]. Group 2: Company Background - BrainsWay is a leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5]. - The company has obtained three FDA-cleared indications for its treatments, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - BrainsWay is committed to advancing neuroscience and increasing global awareness of Deep TMS [5].

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company") today announced the sale of two NIRLAB SA ("NIRLAB") drug analysis devices to a First Nation community to support local safety, health, and emergency-response initiatives. The deployment of two additional NIRLAB devices expands access to rapid, field-deployable drug identification technology within Indigenous communities, enabling informed decision-ma ...